236 related articles for article (PubMed ID: 35756636)
1. Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer.
Bleve S; Cursano MC; Casadei C; Schepisi G; Menna C; Urbini M; Gianni C; De Padova S; Filograna A; Gallà V; Rosti G; Barone D; Chovanec M; Mego M; De Giorgi U
Front Oncol; 2022; 12():910087. PubMed ID: 35756636
[TBL] [Abstract][Full Text] [Related]
2. Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy.
Fankhauser CD; Sander S; Roth L; Gross O; Eberli D; Sulser T; Seifert B; Beyer J; Hermanns T
Br J Cancer; 2018 Mar; 118(6):825-830. PubMed ID: 29485982
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer.
Ribnikar D; Stukalin I; Bedard PL; Hamilton RJ; Jewett M; Warde P; Chung P; Anson-Cartwright L; Templeton AJ; Amir E; Hansen AR; Heng DYC; Lewin J
Curr Oncol; 2020 Dec; 28(1):107-114. PubMed ID: 33622996
[TBL] [Abstract][Full Text] [Related]
4. Can we predict chemotherapy response in patients with metastatic testicular cancer? Role of thrombocytosis as a novel marker.
Gokce MI; Mermerkaya M; Süer E; Afandiyev F; Baltaci S
Minerva Urol Nefrol; 2017 Aug; 69(4):342-348. PubMed ID: 27733750
[TBL] [Abstract][Full Text] [Related]
5. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
Gillessen S; Sauvé N; Collette L; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Beyer J;
J Clin Oncol; 2021 May; 39(14):1563-1574. PubMed ID: 33822655
[TBL] [Abstract][Full Text] [Related]
6. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group.
Winter C; Pfister D; Busch J; Bingöl C; Ranft U; Schrader M; Dieckmann KP; Heidenreich A; Albers P
Eur Urol; 2012 Feb; 61(2):403-9. PubMed ID: 22078334
[TBL] [Abstract][Full Text] [Related]
7. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
8. Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment.
Fankhauser CD; Gerke TA; Roth L; Sander S; Grossmann NC; Kranzbühler B; Eberli D; Sulser T; Beyer J; Hermanns T
J Cancer Res Clin Oncol; 2019 Mar; 145(3):781-785. PubMed ID: 30637464
[TBL] [Abstract][Full Text] [Related]
9. Detection of Circulating Tumor Cells (CTCs) in Patients with Testicular Germ Cell Tumors.
Nastały P; Honecker F; Pantel K; Riethdorf S
Methods Mol Biol; 2021; 2195():245-261. PubMed ID: 32852768
[TBL] [Abstract][Full Text] [Related]
10. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.
J Clin Oncol; 1997 Feb; 15(2):594-603. PubMed ID: 9053482
[TBL] [Abstract][Full Text] [Related]
11. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
Sonneveld DJ; Hoekstra HJ; van der Graaf WT; Sluiter WJ; Mulder NH; Willemse PH; Koops HS; Sleijfer DT
Cancer; 2001 Apr; 91(7):1304-15. PubMed ID: 11283931
[TBL] [Abstract][Full Text] [Related]
12. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
[TBL] [Abstract][Full Text] [Related]
13. DNA damage levels in peripheral blood mononuclear cells before and after first cycle of chemotherapy have comparable prognostic values in germ cell tumor patients.
Ivovič D; Šestáková Z; Roška J; Kálavská K; Hurbanová L; Holíčková A; Smolková B; Kabelíková P; Novotná V; Chovanec M; Palacka P; Mego M; Jurkovičová D; Chovanec M
Front Oncol; 2024; 14():1360678. PubMed ID: 38496757
[TBL] [Abstract][Full Text] [Related]
14. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
15. Management of metastatic germ cell tumors.
Hussain SA; Ma YT; Cullen MH
Expert Rev Anticancer Ther; 2008 May; 8(5):771-84. PubMed ID: 18471049
[TBL] [Abstract][Full Text] [Related]
16. Disease Characteristics and Treatment Outcome of Testicular Germ Cell Tumors Treated with Platinum-Based Regimens.
Sattar A; Masood M; Nisar H; Fatima I; Shahid AB
J Coll Physicians Surg Pak; 2018 Apr; 28(4):292-296. PubMed ID: 29615170
[TBL] [Abstract][Full Text] [Related]
17. [Using preorchiectomy tumor marker serum concentrations for International Germ Cell Consensus Classification (IGCCCG) risk group assignment results in significant numbers of up- and downstaging].
Paffenholz P; Nestler T; Maatoug Y; von Brandenstein M; Köditz B; Pfister D; Heidenreich A
Urologe A; 2021 Mar; 60(3):337-343. PubMed ID: 33427889
[TBL] [Abstract][Full Text] [Related]
18. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
Bokemeyer C
Oncology; 1998; 55(3):177-88. PubMed ID: 9560052
[TBL] [Abstract][Full Text] [Related]
19. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.
Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M
BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of testicular germ cell tumors relapse].
Carbonnaux M; Vinceneux A; Peyrat P; Fléchon A
Bull Cancer; 2020 Sep; 107(9):912-924. PubMed ID: 32653158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
